Cleveland Clinic First-In-Human Trial of CRISPR Gene-Editing Therapy Shown to Safely and Continuously Lower Cholesterol and Triglycerides After One Year
A Cleveland Clinic Phase 1, first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using CRISPR-Cas9 was effective and safe in reducing LDL (“bad”) cholesterol and triglycerides in people with medication-resistant lipid disorders through one-year of follow-up with all doses.